LDS/Medical Tests/Acid Phosphatase, Total, Serum

Acid Phosphatase, Total, Serum

Acid phosphatase (ACP), also known as total acid phosphatase, is present in many tissues but the greatest concentrations of ACP activity occurs in prostate, bone, spleen, platelets, and erythrocytes. Plasma ACP comprises mainly five distinct isoenzymes: lysosomal, prostatic, erythrocytic, macrophagic and osteoclastic. Prostatic acid phosphatase (PAP), is a glycoprotein synthesized by the prostate gland and belongs to a family of the acid phosphatase enzymes actively participating in hydrolysis of phosphate esters in a low Ph (< 7.0). PAP I usually is elevated in patients with prostate cancer, especially in metastatic cancers. Since ACP is secreted by white blood cells (especially monocytes) elevated levels are also seen in lymphoproliferative disorders such as hairy cell leukemia.

Elevated levels of lysosomal isoforms can be seen in lysosomal storage diseases such as Gaucher and Niemann-Pick disease, whereas osteoclastic can be seen in bone cancer. Acid phosphatase is also found in seminal fluid and is the only test that can be used to investigate alleged rape. ACP can be normally detected as total ACP in the plasma due to physiological turnover of the cells. However, a marked increase in the concentration of ACP can be seen in diseases involving tissues that express higher activity of ACP. Total serum ACP is not specific to any particular tissue as it includes all of its isoenzymes; however, it can be also used as a marker in diagnosis of storage diseases, lymphoproliferative disorders and related diseases. The primary use of PAP for the diagnosis of prostate cancer has been replaced by the use of prostate specific antigen (PSA); however, it can be still used for predicting recurrence after radical prostatectomy for clinically localized prostate cancer and following response to androgen ablation therapy, when used in conjunction with PSA.

  • Predicting recurrence after radical prostatectomy for clinically localized prostate cancer and following response to androgen ablation therapy when used in conjunction with prostate-specific antigen
  • Total acid phosphatase can be used as a tumor marker for storage disease and other related diseases
  • For legal reasons in rape cases

Increased in:

  • Osteoclastoma (giant cell tumor)
  • Osteopetrosis (marble bone disease)
  • Paget’s disease
  • Hyperparathyroidism
  • Bone metastasis
  • Gaucher’s disease
  • Niemann-Pick disease
  • Prostatic carcinoma
  • Metastatic carcinoma of prostate
  • Metastatic bone cancer
  • Multiple myeloma
  • Prostatitis
  • Benign prostatic hyperplasia (BPH)
  • Prostatic infarction
  • Sickle cell anemia
  • Liver cirrhosis
  • Lymphoproliferative disorders

Adults

< 4.3 U/L (Acid phosphatase, total)

< 3.5 ng/mL (Prostate acid phosphatase)

<2U/L in vaginal fluid

Quantitative enzymatic, Immunoassay, Radioimmunoassay (RIA), Enzyme immunoassay.

Serum (SST tube). 

Stability

  • Ambient: Unacceptable
  • Refrigerated: Unacceptable
  • Frozen: 1 month

Note: Some isoenzymes are thermolabile; therefore, separate serum within 30 minutes and store frozen. Avoid hemolysis. Acidification of the serum to a pH below 6.5 can stabilize the enzyme activity.

Prostate Specific Antigen, total and free, C-telopeptide of type I collagen (CTx), Procollagen type I N-terminal propeptide (P1NP), deoxypyridinoline (DPD), tartrate-resistant acid phosphatase (TRAP), alkaline phosphatase (ALP), osteocalcin.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Am J Med. 1959;27:902-10. [PMID: 13845841]
  • Urol Clin North Am. 1979;6:629-41. [PMID: 388794]
  • Mol Pathol. 2002;55:65-72. [PMID: 11950951]
  • Panteghini M, Bais R. Serum Enzyme. Textbook of Clinical Chemistry and Molecular Diagnostics, 5th ed. 2012: 565-98.